News coverage about Inogen (NASDAQ:INGN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inogen earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the medical technology company an impact score of 45.7129632349036 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s rankings:
- Inogen, Inc. (INGN) – Momentum Stock to Focus – Wall Street Morning (wallstreetmorning.com)
- Critical Survey: Inogen (INGN) versus VWR (VWR) (americanbankingnews.com)
- Inogen (INGN) Lifted to Buy at Zacks Investment Research (americanbankingnews.com)
- Monthly Losing stock – Inogen, Inc. (INGN) returned -2.71% negative – The Stocks News (press release) (thestocksnews.com)
A number of research firms have recently weighed in on INGN. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Leerink Swann reaffirmed an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. BidaskClub cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Finally, Needham & Company LLC lifted their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Inogen currently has an average rating of “Hold” and an average target price of $102.71.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same period in the prior year, the firm earned $0.25 earnings per share. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. analysts expect that Inogen will post 1.19 EPS for the current fiscal year.
In other Inogen news, Director Ray Benjamin M. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total value of $119,060.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $119,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Byron Myers sold 35,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $116.77, for a total value of $4,086,950.00. Following the completion of the transaction, the executive vice president now owns 48,600 shares of the company’s stock, valued at approximately $5,675,022. The disclosure for this sale can be found here. Insiders sold 67,500 shares of company stock valued at $7,950,715 over the last three months. Corporate insiders own 5.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Inogen (INGN) Receives News Sentiment Rating of 0.09” was reported by BBNS and is the property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://baseballnewssource.com/markets/inogen-ingn-given-daily-coverage-optimism-rating-of-0-09/1820187.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with our FREE daily email newsletter.